Ivy Brain Tumor Center Expands Global Phase 3 Gliofocus Study to the EU and Additional U.S. States
15. Januar 2025 09:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gliofocus Study is now open in Paris and Madrid. The global Gliofocus network includes 68 EU medical centers. In the United States, The...
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries
09. Januar 2025 10:53 ET
|
Research and Markets
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "NUT Midline Carcinoma Treatment Market by Treatment, by Route of Administration, by End-User, and By Region" report has been added to ...
invIOs to present progress across oncology pipeline during JP Morgan Week 2025
16. Dezember 2024 09:00 ET
|
invIOs GmbH
VIENNA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in...
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
26. November 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
25. November 2024 07:00 ET
|
IN8bio, Inc
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18. November 2024 08:00 ET
|
Trogenix
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the...
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18. November 2024 02:00 ET
|
Trogenix
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the...
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
14. November 2024 16:15 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
06. November 2024 07:30 ET
|
Plus Therapeutics Inc.; Spectron RX
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
05. November 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024